Drug Type Small molecule drug |
Synonyms OPM 101, OPM101 |
Target |
Action inhibitors |
Mechanism RIPK2 inhibitors(Serine/threonine-protein kinase RIPK2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystitis, Interstitial | Phase 1 | France | - | |
Inflammatory Bowel Diseases | Phase 1 | France | - | |
Neoplasms | Phase 1 | France | - |
Not Applicable | - | - | qrqdlsylpq(rdondwsedq) = jwwxcdvbsk yvaispavzm (sbjrggbkep ) View more | - | 13 Oct 2024 | ||
Corporate Publications Manual | Phase 1 | - | 104 | hjwugydhhm(hxnqqxmmfz) = rtgyizvlpe vksgolrpck (iaqicnimmd ) View more | Positive | 16 Jul 2024 | |
Placebo | - |